Find Clinical Trials & Studies

Visit the Research & Education Institute

HLX10 plus Chemotherapy (Carboplatin- Etoposide) in comparison with Atezolizumab plus Chemotherapy

I'm Interested!

Please call
1-800-641-2422

A Randomized, Open-label Study of HLX10 plus Chemotherapy (Carboplatin- Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES SCLC) (ASTRIDE)

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Lung

Study Purpose

This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: - Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) - Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)

Principal Investigator
Afshin Dowlati MD

Department/Division
Cancer (Thoracic)

UH IRB: Pro00073518
StudyID: SHB1523
ClinicalTrials.gov: NCT05468489

I'm Interested!

Please call
1-800-641-2422

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422